advertisement
Abstract #15873 Published in IGR 2-3
Contralateral effect of topical β-adrenergic antagonists in initial one-eyed trials in the Ocular Hypertension Treatment Study
Piltz J; Gross R; Shin DH; Beiser JA; Dorr DA; Kass MA; Gordon MOAmerican Journal of Ophthalmology 2000; 130: 441-453
PURPOSE: To evaluate the magnitude of the contralateral effect of topically administered beta blockers on intraocular pressure (IOP). METHODS: The Ocular Hypertension Treatment Study enrolled 1636 subjects. Of these, 817 were randomized to receive topical ocular hypotensive medication, and 819 were randomized to close observation (i.e., no topical medication). The authors compared the IOP of the contralateral eye of subjects at the baseline visit and after an initial one-eyed therapeutic trial of topical beta blockers. They examined differences between baseline and follow-up IOP in untreated eyes of subjects randomized to close observation. RESULTS: The mean reduction in IOP in the beta blocker-treated eyes was -5.9 ± 3.4 mmHg (-22 ± 12%; Student's t test, p < 0.0001). In the contralateral eyes, mean IOP reduction was -1.5 ± 3.0 mmHg (-5.8 ± 12%; p < 0.0001). Of the contralateral eyes, 35% showed a reduction of 3 mmHg or more, and 10% showed a reduction of 6 mmHg or more. The contralateral effect of the relatively selective beta blocker betaxolol did not differ from that of any of the nonselective beta blockers. Factors associated with the magnitude of the contralateral effect were the degree of IOP reduction in the treated eye and baseline IOP of the contralateral eye. In the close observation group, no significant reduction in IOP was noted between the baseline and follow-up visit. CONCLUSIONS: The contralateral effect is important in clinical practice and in clinical trials when the hypotensive effect of a topical beta blocker is evaluated by means of a one-eyes therapeutic trial.
Dr. M.O. Gordon, Department of Ophthalmology and Visual Sciences, Washington University School of Medicine, Box 8203, 660 S Euclid, St Louis, MO 63110-1093, USA. mae@vrcc.wustl.edu
Classification:
9.2.1 Ocular hypertension (Part of: 9 Clinical forms of glaucomas > 9.2 Primary open angle glaucomas)
11.3.4 Betablocker (Part of: 11 Medical treatment > 11.3 Adrenergic drugs)
